2024 Multidisciplinary Head and Neck Cancers Symposium
Expert Point of View: Glenn J. Hanna, MD
Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program), medical oncologist at the Center for Head & Neck Oncology at Dana-Farber Cancer Institute, ...
Can HPV Circulating Tumor DNA Guide Adjuvant Treatment of Oropharyngeal Cancer?
Although so-called liquid biopsies are now helping to determine the need for adjuvant therapy for a number of malignancies, oropharyngeal carcinoma is not yet one of them, according to a prospective p...
Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers
A novel MDM2 inhibitor has demonstrated antitumor activity in progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented at the 2024 Multidisciplinary Head and Nec...
Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC
Marcin R. Dzienis, MBBS, of Australia’s Gold Coast University Hospital, discusses the final analysis of KEYNOTE-B10, a phase IV study in which patients with recurrent or metastatic head and neck squam...
HPV-Associated Oropharyngeal Cancer: Intratreatment FDG-PET Response as a Biomarker for De-escalation of Radiotherapy
The use of imaging midtreatment for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma may guide the use of deintensified chemoradiotherapy, according to a phase II study from...
Novel MDM2 Inhibitor for Salivary Gland Cancers
A novel MDM2 inhibitor, APG-115 (alrizomadlin), has demonstrated antitumor activity and good tolerability in patients with progressive salivary cancer, particularly adenoid cystic carcinoma, according...
Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report
Dan P. Zandberg, MD, of UPMC Hillman Cancer Center, discusses study results showing that, although efficacy was low with both nivolumab plus ipilimumab and nivolumab plus relatlimab in patients with r...
Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer
Samuel Regan, MD, and Benjamin Rosen, PhD, both of the University of Michigan, discuss results from a phase II trial showing the possibility of de-escalating chemoradiation treatment for patients with...
Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance
Eleni M. Rettig, MD, of Brigham and Women’s Hospital, discusses the promising but thus far limited data on using circulating tumor HPV DNA for early detection of HPV-related oropharyngeal cancers, whi...
Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer
Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses the results of the NDURE study, which explored the delays in starting postoperative radiation therapy in patients with...
Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors
Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses body image distress, a source of significant morbidity among head and neck cancer survivors. He recommends strategies ...
HPV-Associated Oropharyngeal Cancer: Adjuvant Treatment Deintensification
Postoperative adjuvant therapy—both chemoradiotherapy and radiotherapy alone—for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma may be safely de-escalated, according to re...
Lenvatinib Plus Pembrolizumab Fails to Improve Overall Survival in Recurrent or Metastatic Head and Neck Cancer
Adding the multikinase inhibitor lenvatinib to the PD-1 inhibitor pembrolizumab as initial therapy for recurrent or metastatic head and neck squamous cell carcinoma improved response rates and progres...
Can HPV ctDNA Guide the Adjuvant Treatment of Oropharyngeal Cancer?
Although liquid biopsies are now helping determine the need for adjuvant therapy in a number of malignancies, they have yet to prove useful in the setting of oropharyngeal carcinoma, according to a pr...
Pooja Karukonda, MD, on Coping With Financial Toxicity in Head and Neck Cancer
Pooja Karukonda, MD, of Duke University Medical Center, discusses findings from the PaRTNer study, which addressed the large financial burden faced by patients with head and neck cancer undergoing rad...
Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck
Nabil F. Saba, MD, of Emory University, discusses phase II study results suggesting parenteral administration of TK-90 may be an effective strategy for preventing radiation-induced oral mucositis in p...
Christopher A. Barker, MD, on New Data on Vismodegib and Radiotherapy for Basal Cell Carcinoma of the Head and Neck
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II study results showing that patients with locally advanced, unresectable basal cell carcinoma of the head and ne...
Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib
Nabil F. Saba, MD, of Emory University, discusses study findings on 2-year survival rates in patients with recurrent metastatic head and neck squamous cell carcinoma who received pembrolizumab plus ca...
